

Wednesday 07 February



Forum Programme


Asian Forum, Hong Kong The Renaissance Harbour View Hotel

Shire

And so we dare

We are championing the fight against under-recognized eye conditions. We believe there's a better future for people living with and affected by ophthalmic diseases. And for us that means having the courage to do things differently.

Find out more at shire.com



Welcome

Ophthalmology Futures Asian Forum 2018

Dear Colleagues,

Welcome to Ophthalmology Futures Asian Forum 2018.

We are delighted to be hosting our third Asian Forum in Hong Kong, one of the world's most dynamic financial centres.

Our Forums aim to present a new perspective on innovation in Ophthalmology, combining small company presentations, research and development updates, market opportunities and pearls for success in the ophthalmology sector.

Our panel discussions on clinical topics will continue with our previous format of clinician-driven questioning to various stakeholders in the innovation cycle. Our business panels will focus both on early stage innovation as well as advice to small company executives hoping to attract attention from larger corporations. We will endeavour to make the meeting as interactive as possible. As always, we would like to thank our advisory board, programme committee, corporate presenters, sponsors and eminent faculty for their invaluable support and assistance without which this meeting would not be possible.

Thank you for joining us in Hong Kong!

The Ophthalmology Futures Team



Vision Futures Limited, London, UK. Registered in England No: 8125858.



Asian Forum 2018 programme

Speakers' affiliations can be found on the inside back cover.

> 08:30 - 08:40

Welcome from Ophthalmology Futures Forums and the Hong Kong Ophthalmological Society

Keith Barton (London, UK)

Dexter Leung (Hong Kong, China)

Kuldev Singh (Stanford, USA)

Chelvin Sng (Singapore)

> 08:40 - 08:50

Guest of Honour

Prof. Anthony Wu (胡定旭教授) GBS JP Standing Committee Member Chinese People's Political Consultative Conference National Committee

> 08:50 - 09:00

The Changing Healthcare Market in Asia

Hogan Wan (JP Morgan)

> 09:00 - 09:30

Skynet and the Eye: Retinal Imaging and Artificial Intelligence

Co-chairs

Tien Yin Wong (Singapore) and Adnan Tufail (London, UK)

Panellists

Robert Chang (Stanford, USA) Almira Chabi (Santen) Sujay Debnath (Carl Zeiss Meditec) Sanny Yuzhen Jiang (London, UK) Ian Wong (Hong Kong, China) Benny Zee (Hong Kong, China) Haogang Zhu (Beijing, China) > 09:30 - 10:40

Small Private Company Presentations 1

Co-chairs

Robert Chang (Stanford, USA) and Dexter Leung (Hong Kong, China)

Companies

09:30-09:37 Sibionics
09:37-09:44 Kali Care
09:44-09:51 Heartisans
09:51-09:58 Pleryon
09:58-10:05 Sonikure
10:05-10:12 EyeYon Medical
10:12-10:19 Medhydrogel
10:19-10:26 China Grand Pharmacuetical and Healthcare
10:26-10:40 Discussion

> 10:40 - 11:05

The Myopia Epidemic: Opportunities and Potential Solutions

Chair

Marcus Ang (Singapore)

Panellists

Pauline Cho (Hong Kong, China)
Mingguang He (Melbourne, Australia)
Shigeru Kinoshita (Kyoto, Japan)
Saw Seang Mei (Singapore)
Naveed Shams (Santen)
Donald Tan (Singapore)

> 11:05 - 11:25

Networking Break

Sponsored by Santen

> 11:25 - 11:50

What are the Prospects for the Ocular Surface?

Chair

Shigeru Kinoshita (Kyoto, Japan)

Panellists

Tommy Chan (Hong Kong, China) Robert Dempsey (Shire) Jimin Lee (Bausch + Lomb) Zuguo Liu (Xiamen, China) Lipika Roy (Allergan) Carol Stiff (Santen)

> 11:50 - 12:15

The Regulatory Pathways in China

Chair

Tina Wong (Singapore)

Panellists

Jane Ellen Giamporcaro (Glaukos) Yougin Tian (Santen) Ningli Wang (Beijing, China) Dietrich Wolf (EyeTechCare)

> 12:15 - 12:45

Wooing Asian Investors

Co-chairs

Dennis Lam (Hong Kong, China) Fay Xing (Wuxi Ventures)

Panellists

Yuval Binur (Arsuf Global Advisers) Sylvia He (Hyfinity Fund, Beijing) Yen-Chen Huang (Diamond Biofund, Taipei) Richel Liu (Rimonci Capital, Beijing) Satoshi Suzuki (Santen) Hogan Wan (JP Morgan)

> 12:45 - 13:20

Networking Lunch and Company Exhibition

> 13:20 - 13:40

How Will the Glaucoma **Device Boom Affect Asia?**

Chair

Keith Barton (London, UK)

Panellists

Robert Ang (Manilla, Philippines) Almira Chabi (Santen), Mike Chodzko (Ivantis) Dexter Leung (Hong Kong, China) Baldo Sforzolini (Allergan) Chelvin Sng (Singapore) Jay Stark (Alcon) Xiulan Zhang (Guangzhou, China)

> 13:40 - 14:00

Will New Modes of Glaucoma **Drug Delivery Eclipse the Device Boom?**

Chair

Tina Wong (Singapore)

Panellists

Robert Ang (Manilla, Philippines) Jane Ellen Giamporcaro (Glaukos) Paul Kaufman (Madison, USA) Baldo Sforzolini (Allergan) Xiulan Zhang (Guangzhou, China)

> 14:00 - 15:10

Small Private Company Presentations 2

Chair

Chelvin Sng (Singapore)

Companies

14:00-14:07 EyeTechCare 14:07-14:14 **Belkin Lasers** 14:14-14:21 **Implandata** 14:21-14:28 Ivantis 14:28-14:35 **BCVA** 14:35-14:42 Orca Surgical 14:42-14:49 Emmetrope 14:49-14:56 Akkolens 14:56-15:03 Mynosys 15:03-15:10 Discussion

> 15:10 - 15:30

The Changing Market for Refractive Surgery

Chair

Jodbhir Singh Mehta (Singapore)

Panellists

Marcus Ang (Singapore)
Joe Redner (Carl Zeiss Meditec)
Sunil Shah (Birmingham, UK)
Roland Zaha (Alcon)
Wang Zheng (Aier Hospital Group, China)

> 15:30 - 15:50

Networking Break

Sponsored by Shire

> 15:50 - 16:15

Presbyopia and Cataracts: Femto, Eydrops and Accommodating IOL's

Chair

Sunil Shah (Birmingham, UK)

Panellists

Robert Ang (Manilla, Philippines)
Jan Willem de Cler (Carl Zeiss Meditec)
Paul Kaufman (Madison, USA)
Jodbhir Singh Mehta (Singapore)
Calvin Roberts (Bausch + Lomb)

> 16:15 - 16:25

Ophthalmic Innovation Case Study: C-Mer Holdings

Chair

Keith Barton (London, UK)

Speaker

Dennis Lam (Hong Kong, China)

> 16:25 - 16:55

A View from Global Corporate Leaders

Chair

Keith Barton (London, UK)

Panellists

Jan Willem de Cler (Carl Zeiss Meditec) Robert Dempsey (Shire) Calvin Roberts (Bausch + Lomb) Baldo Sforzolini (Allergan) Naveed Shams (Santen)

> 16:55 - 17:00

Concluding Remarks

Keith Barton (London, UK)

Dexter Leung (Hong Kong, China)

Kuldev Singh (Stanford, USA)

Chelvin Sng (Singapore)

> 17:00 - 18:30

Cocktail Reception

This Ophthalmology
Futures Forum is a
fantastic platform
for all the stakeholders to be
coming here and meeting and
sharing ideas.

Tina Wong, Senior Consultant, Singapore National Eye Centre "



Information for patients about Minimally Invasive Glaucoma Surgery

migs.org proud sponsors of Ophthalmology Futures









MIGS.org







+44 (0)203 714 1762 info@medether.com www.medether.com



MedEther is a platform connecting UK hospitals and senior medical professionals with a wide network of hospitals in 20+ provinces of China and more than 7 million Chinese healthcare professionals. MedEther works with medical education and training organisations to help produce education programs that are eccessible and understandable for Chinese healthcare professionals. We aim to create a network of shared knowledge between the UK and Chinese consultants, both in terms of a digital database and the direct transfer of knowledge through lectures, seminars,

In clinical service, MedEther works with medical professionals in both the UK and China to provide cross-border co-management service to Chinese patients via organising both feleconsultation and visiting consultant programs.

MedEther has established strategic partnerships with well-known Chinese organisations providing continuing medical courses to deliver CPD accredited education programs to more than 5 million users in China. We also help UK senior doctors explore and set up multiple practiong sites in China.

This year, MedEther has launched a series of training and skill showcase events for Chinese medical professionals who have subspecialty interest in plastic surgeries, non-surgical aesthetic treatment and cosmetic medicine. We invite senior plastic surgeons, dermatologists with cosmetic practice and medical aesthetic doctors to join us in this project and visit China for: (1) providing education-training/teaching to medical professionals: (2) providing clinical services to high net-worth individuals or patients suffering complex medical conditions in China.

Please visit our website for more information



REIMAGINING EYE CARE

Alcon's mission is to discover new ways to enhance sight and improve people's lives, and we have done this successfully for 70 years.

Our products touch the lives of millions of people each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

Reimagining eye care means to us that we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world.

Learn more at www.alcon.com

CONNECT WITH US!



@AlconEyeCare



@Alcon





Upcoming European and Asian Forums

Ophthalmologist driven forums with corporate leaders, financiers, regulators, clinicians and scientists gathered to facilitate innovative ophthalmic product development and improve eye care delivery.

The audience includes senior business development and management representatives from start-up, small and large ophthalmic device and pharmaceutical companies, in addition to investors, bankers, regulators, reimbursement specialists, contract research organisation representatives, business consultants, scientists and clinicians.

At our forums we endeavour to create a program that is driven by clinical unmet need, is interactive and of interest to all attending parties. **Supporting improved ocular health**.

Single and joint event sponsorship packages available. Please email **info@ophthalmology-futures.com** for further information.

European Forum 2018 - Vienna


Save the date

Thursday 20 September 2018

Registration now open

> ophthalmology-futures.com





Our Platinum Sponsors



As a pharmaceutical company specialized in the field of ophthalmology, Santen is committed to developing innovative ophthalmologic drugs that contribute to the improvement of Quality of Life and Quality of Vision of patients around the world. Santen creates competitive therapies by selectively channeling resources into three therapeutic categories-corneal and conjunctival epithelial disorders, glaucoma and hypertension, and retinal disorders-as we deem these markets to have high unmet medical needs and strong growth prospects. We are pursuing various strategies in order to achieve our long term strategic vision towards 2020, to become a Specialized Pharmaceutical Company with a Global Presence. To realize this vision, we are strengthening our pipeline of compounds for development, building a global clinical development system, and investing in the development of new businesses in the rapidly growing markets in EMEA and Asian countries including Japan, where we can best maximize our strengths.

For more information, please visit www.santen.com

Our Gold Sponsors



Alcon is the global leader in eye care. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our products touch the lives of more than 285 million people each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors, and there are millions more who are waiting for solutions to meet their eye care needs. Our purpose is reimagining eye care, and we do this through innovative products, partnerships with eye care professionals and programs that enhance access to quality eye care.

For more information, please visit www.alcon.com

Our Platinum Sponsors



Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people's lives with medicines that have a meaningful impact on patients and all who support them on their journey.

For more information, please visit www.shire.com



Johnson Johnson vision

Johnson & Johnson Vision, through its operating companies, is committed to improving and restoring sight for patients worldwide. Since debuting the world's first disposable soft contact lens in 1987, Johnson & Johnson Vision Care, Inc. has been helping patients see better through their world-leading ACUVUE® Brand Contact Lenses portfolio. In 2017, with the addition of Abbott Medical Optics, Inc., the Johnson & Johnson Surgical Vision business, Johnson & Johnson invested further in eye health by expanding into cataract surgery, laser refractive surgery (LASIK) and consumer eye health. Serving more than 60 million patients a day across 103 countries, Johnson & Johnson Vision is committed to helping more people in more places improve or restore their sight. Dual headquartered in Jacksonville, Florida, and Santa Ana, California, Johnson & Johnson Vision has more than 10,000 employees worldwide.

For more information, please visit www.vision.abbott

BAUSCH+LOMB

Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.

For more information, please visit www.bausch.com



The Medical Technology business of ZEISS offers complete solutions, including implants and consumables, to diagnose and treat eye conditions and ophthalmic diseases. The comprehensive ZEISS portfolio is designed to meet the demands of eye care professionals and help them deal with an increasingly challenging healthcare environment.

The company drives the development of leading edge technology for diagnosis, treatment, follow-up and management of the most common eye diseases - all with the goal of helping health care professionals overcome their day-to-day challenges so they can focus on delivering the best possible patient care..

For more information, please visit www.zeiss.com/meditec-ag

Our Bronze Sponsor



Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing gamechanging ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 55+ mid-to-late stage pipeline programs currently in development.

For more information, please visit www.allergan.com





An Ophthalmologist driven forum of corporate leaders, financiers, regulators, clinicians and scientists gathered to facilitate innovative ophthalmic product development and improve eye care delivery.

Supporting improved ocular health

Supported Charities



Every 15 minutes, someone in the UK starts to lose their sight.

At Moorfields Eye Charity, we believe that we can help bring new treatments to patients with eye diseases faster than ever before. By raising funds for the crucial research, education and patient care at Moorfields Eye Hospital and its research partner, the UCL Institute of Ophthalmology, we are able to help ensure that they remain at the forefront of ophthalmic care and research.

- Help Moorfields Eye Hospital provide the best possible care for its patients
- Invest in state-of-the-art equipment
- Educate the researchers and clinicians of tomorrow
- Fund research to find better and more effective treatments for blinding diseases

>> moorfieldseyecharity.org.uk



We provide help to everyone affected by sight loss from glaucoma.

Our information is for everyone who is interested in glaucoma, people who have just been diagnosed, or anyone living with glaucoma.

We run a helpline, provide free glaucoma leaflets, set up patient support groups, provide a buddying scheme and fund professional research that helps with the detection, management and treatment of glaucoma.

We also run glaucoma awareness campaigns and have a membership scheme, which helps people keep up to date about their condition and treatment.

All our services are free, funded through our members' generosity.

>> glaucoma-association.com



Ophthalmology Futures European Forum

An Ophthalmologist driven forum of corporate leaders, financiers, regulators, clinicians and scientists gathered to facilitate innovative ophthalmic product development and improve eye care delivery. **Supporting improved ocular health.**

Save The Date Thursday 20 September 2018

The Hilton Danube Waterfront Hotel Vienna, Austria



Registration Now Open

> ophthalmology-futures.com

We endeavour to create an interactive program that is driven by unmet clinical need and of interest to all parties.

Key focus areas for the 2018 European Forum will include:

- Gene Replacement Vs Protein Therapy for Retinal Disease: Targets, Challenges and Business Strategies
- Artificial Intelligence
- Will Genericisation of Dry Eye Drugs Impact Investment?
- Fewer Injections, Better Outcomes with Anti-VEGF Drugs –
 Can You Have Your Cake and Eat It?
- What Drives Investor Interest in Ophthalmology. Why and Where?
- Will Bleb-Formation Divide the MIGS Market?
- Novel Pharmacological Therapy for Presbyopia, Cataract and Other Forms of Ageing
- The Quality Vs Efficiency Tradeoff with Modern Cataract Surgery Technology
- Drug Delivery for Glaucoma: Pending Reality or Passing Fantasy?
- Will Any IOL Technology Company Remain Unsold?
- Private Company Presentations
- Shark Tank
- A View from the Top Corporate CEOs Interviewed

For further information and to register, please visit:

> ophthalmology-futures.com

Exclusive Forum Content Is Now Available Online

Content from our past Forums is now available on our website, to view please visit:

> ophthalmology-futures.com



>> ophthalmology-futures.com/lisbon-2017-videos



>> ophthalmology-futures.com/singapore-2017-videos



>> ophthalmology-futures.com/singapore-2017-highlights



The European Forum 2017 overview, as well as a full video catalogue of the speakers from the day is available. Key focus areas included:

- Dry AMD: Current challenges and future trends
- Pearls for innovation
- Perspectives from top venture capitalists
- Presbyopia: More than just lenses?
- Who should you talk to in order to sell your company?
- And many more.

The Asian Forum 2017 overview, as well as a full video catalogue of the speakers from the day is available. Key focus areas included:

- Dry AMD: Current challenges and future trends
- Developing and taking a new idea to market
- The future of anti-microbials enough of our -cins
- A view from the top: Ophthalmic innovation
- The Asian investment climate
- And many more.

Keith Barton from Ophthalmology Futures Forums was granted an exclusive interview with Dr. Flemming Ornskov, CEO of Shire PLC.

To view the interview and the summary highlights from the 2017 Asian Forum panel sessions, please visit the link below:

>> ophthalmology-futures.com/ singapore-2017-highlights

Programme Advisory Committee

- Ike Ahmed Division Head,
 Ophthalmology, Trilium Health
 Partners, Assistant Professor,
 University of Toronto, Clinical
 Assistant Professor, University
 of Utah, USA.
- Jorge Alio Professor and Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Vissum Corporation, Spain.
- Gerd Auffarth Chairman,
 Department of Ophthalmology,
 University of Heidelberg, Germany.
- Francesco Bandello Full Professor and Chairman Department of Ophthalmology, Ospedale San Raffaele of Milan, Italy.
- Beatrice Cochener Professor and Chairman, Ophthalmology Department, University Hospital Brest, France.
- Paul Chew Professor of Ophthalmology, National University of Singapore, Singapore.
- Jack Holladay Clinical Professor of Ophthalmology at Baylor College of Medicine Houston, USA.
- Frank Holz Director and Chairman Universitäts-Augenklinik Bonn, University of Bonn, Germany.

- Jost Jonas Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.
- Sir Peng Khaw Professor of Glaucoma and Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, UK.
- Richard Lindstrom Founder and Attending Surgeon, Minnesota Eye Consultants, Adjunct Professor Emeritus, University of Minnesota, Past President, ASCRS, ISRS\AAO; IIIC, IRSC, Chief Medical Editor, Ocular Surgery News, USA.
- Anat Loewenstein Vice Dean, Sackler Faculty of Medicine, Tel Aviv University and Chairman of Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel.
- Boris Malyugin Chief of Department of Cataract and Implant Surgery, Deputy Director General, S. Fyodorov Institute, Russia.

- Paul Rosen Consultant Ophthalmic Surgeon Oxford Radcliffe Hospital NHS Trust and Senior Lecturer, University of Oxford, UK.
- José-Alain Sahel Director, Vision Institute and Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris; and Cumberlege Professor of Biomedical Science, University College London, UK.
- Sanny Yuzhen Jiang Honorary Clinical Fellow at Moorfields Eye Hospital and Senior Research Associate at University College London Institute of Ophthalmology, UK.
- **Julian Stevens** Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, UK.
- Donald Tan Medical Director of the Singapore National Eye Centre (SNEC), Professor of Ophthalmology, National University of Singapore, Academic Chair, Ophthalmology Academic Clinical Program, Duke-NUS Graduate Medical School, Singapore.
- **Tien Yin Wong** Medical Director, Singapore National Eye Center, Singapore.

Advisors

- Laurent Attias Senior Vice
 President, Head of Strategy, BD&L and Market Access, Alcon, USA.
- Leonard Borrmann Divisional Vice President Research and Development, Abbott, USA.
- Emmett Cunningham Partner with Clarus Ventures LLC, USA.
- Eugene de Juan Jr. ForSight Labs and University of California, San Francisco, USA.
- Tom Dunlap Supervisory Board Member, i-Optics BV. Executive Vice President, Sand Hill Consulting Associates, USA.
- Malvina Eydelman Director,
 Division of Ophthalmic and Ear,
 Nose and Throat Devices ODE/
 CDRH/FDA, USA.
- Akira Kurokawa CEO and President Santen Pharmaceutical Co. Ltd.

- James Mazzo Global President Ophthalmic Devices, Carl Zeiss Meditec AG, USA.
- Calvin Roberts Executive Vice
 President and Chief Medical Officer
 at Bausch+Lomb, USA.
- Brent Saunders CEO and President, Allergan, USA.
- Baldo Scasselati Sforzolini Senior Vice President of Clinical Development, Allergan, USA.
- Naveed Shams MD, PhD, Head of Global R&D, Chief Scientific Officer, Senior Corporate Officer, Santen, USA.
- Naveed Siddiqi Partner, Edmond de Rothschild Investment Partners, UK.
- John Wilkinson Director of Devices, Medicines and Healthcare Products Regulatory Agency, UK.
- **Fay Xing** Partner, Wuxi Healthcare Ventures, China.

Organising Committee

- Keith Barton Consultant
 Ophthalmologist, Moorfields Eye
 Hospital, UK.
- Donald Budenz Professor and Chairman, Department of Ophthalmology, University of North Carolina, USA.
- Kuldev Singh Professor of Ophthalmology and Director of Glaucoma Service, Stanford University, USA.
- Chelvin Sng Consultant and Assistant Professor, National University Hospital, Singapore.

Operational Team

- Elliott Gibbs Project Manager, MedEther, UK.
- Natasha Nash Executive Assistant to CEO, MedEther, UK.
- Sanny Yuzhen Jiang Honorary
 Clinical Fellow at Moorfields Eye
 Hospital and Senior Research Associate at University College London Institute of Ophthalmology, UK.



Kuldev Singh, Professor of Ophthalmology and Director of Glaucoma Service, Stanford

market analysts."

99



Moorfields Eye Charity supports the incredible and pioneering work of Moorfields Eye Hospital and it's research partner, the UCL Institute of Ophthalmology.

This support is making a difference for patients at the hospital and for people with sight problems around the world.

Call: +44 (0)20 7566 2565 Email: eyecharity@moorfields.nhs.uk Visit our website: www.moorfields.nhs.uk/eyecharity

Registered Charity No: 1140679

Asian Forum 2018 Private Company Presenters

- Akko Lens International BV Michiel Rombach, CEO.
- BCVA
 Laurence Marsteller, MSc.,
 MD. Managing Director.
- BELKIN Laser Ltd.
 Daria Lemann-Blumenthal,
 LL.B., EMBA, CEO.
- China Grand Pharmaceuticial and Healthcare Holdings Ltd. Rocky Shao, CEO.
- Emmetrope Inc.
 Andrew Philips, Clinical
 Associate Professor, University of Southern California, Keck
 School of Medicine.

- Eye Tech Care
 Dietrich Wolf, PhD, CEO,
 Directeur Général.
- EyeYon Medical
 Nahum Ferera, CEO.
- Heartisans Ltd.
 Rupert Mok, Advisor Technical and Clinical Study.
- Implandata Ophthlamic Products GmBH
 Max Ostermeier, CEO.
- Ivantis Inc.
 Michael Chodzko,
 Vice President of Marketing.
- Kali Care
 Sinah Fateh, CEO.

- MedHydrogel
 Anastacia Drebot, Founder.
- Mynosys Cellular Devices
 Tom Dunlap, Board Member.
- Orca Surgical Ltd.
 Yariv Baron, CEO.
- Pleryon
 Yu Yu, Founder and CEO.
- Shenzhen SiBionics Co. Ltd. Yu Zhao, Founder and CEO.
- Sonikure Technology HK Ltd.
 Dr Suen Wai Leung Langston,
 Ph.D, Founder and CEO.

Asian Forum 2018 Panellists and Chairs

> A

Marcus Ang

Consultant Ophthalmologist, Singapore National Eye Centre.

Robert Ang

Refractive Surgery, Cataract, Glaucoma Specialist at Asian Eye Institute, Manilla, Philippines.

> B

Keith Barton

Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Co-chair, Ophthalmology Futures Forums.

> C

Almira Chabi

Senior Director, Global Biomedical Science, Santen Pharmaceutical Co. Ltd.

Tommy Chan

Assistant Professor, Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, China.

· Robert Chang

Assistant Professor of Opthalmoloy, Stanford University Medical Center, Stanford, USA.

Pauline Cho

Professor, School of Optometry, Hong Kong Polytechnic University, Hong Kong, China.

Mike Chodzko

Vice President of Marketing, Ivantis, Inc.

· Jan Willem de Cler

Vice President Surgical Ophthalmology, Medical Technology Business Group, Carl Zeiss Meditec AG.

> D

Sujay Debnath

Regional Director, S.E. Asia Medical Business Group, Carl Zeiss Meditec AG.

· Robert J. Dempsey

Group Vice President, Head of Global Ophthalmics Franchise, Shire Plc.

> F

Emery Fu

CEO, Jyton Consulting, China.

> G

Jane Ellen Giamporcaro

Senior Director, Clinical Research and Medical Affairs, Glaukos Corporation.

· Mike Gu

Managing Director of Osmunda Medical Device Consulting, China.

> H

Mingguang He

Professor, Centre for Eye Research Australia, Melbourne, Australia.

Sylvia He

Senior Partner, Hyfinity Investment Inc., Beijng, China.

Yen-Chen Huang

Vice President at Diamond BioFund Inc., Taipei, Taiwan.

S 1

Sanny Yuzhen Jiang

University College London Senior Research Associate, Moorfields Eye Hospital Clinical Fellow, Founder of MedEther Ltd.

· Chenjin Jin

Deputy Director of Zhongshan Ophthalmic Centre (ZOC); Deputy Director of Fundus Disease Centre of ZOC, Guangzhou, China.

> K

· Paul Kaufman

Professor of Ocular Pharmacology and Chair-Emeritus of the Department of Ophthalmology & Visual Sciences at the University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

· Shigeru Kinoshita

Professor, Kyoto Prefectural University of Medicine, KPUM Department of Ophthalmology, Kyoto, Japan.

> L

· Dennis Lam

Chairman and CEO, Hong Kong C-MER International Eye Care Group Limited, Hong Kong, China.

· Jimin Lee

Director of Clinical Affairs for Asia Pacific, Bausch + Lomb.

· Dexter Yu-Lung Leung

Honorary Consultant & Specialist in Ophthalmology, Department of Ophthalmology, Hong Kong Sanatorium & Hospital. Honorary Clinical Associate Professor, Department of Ophthalmology & Visual Sciences, the Chinese University of Hong Kong. Honorary Clinical Associate Professor, Department of Ophthalmology, The University of Hong Kong Li Ka Shing Faculty of Medicine.

· Richel Liu

Founder and CEO, Rimonci International Ltd.

· Zuguo Liu

Professor and President of Xiamen Medical University; Director of Xiamen Eye Centre, Xiamen, China.

> M

· Jodhbir Singh Mehta

Associate Professor, Head Corneal and External Eye Disease Department and Senior Consultant, Singapore National Eye Centre, Singapore.

Saw Seang Mei

Professor, Saw Swee Hock School of Public Health, Singapore Eye Research Institute and Yong Loo Lin School of Medicine, Singapore.

> R

Joe Redner

Head of Sales, Ophthalmic Devices, Carl Zeiss Meditec AG.

Calvin W. Roberts

Senior Vice President and Chief Medical Officer, Bausch + Lomb.

· Lipika Roy

M.D(ophthal), M.B.A, Associate Vice President, Asia Pacific and Middle East, Chief Medical Office: Allergan.

> S

Baldo Scassellati Sforzolini

Senior VP Clinical Development, Allergan.

Sunil Shah

Consultant Ophthalmic Surgeon at Birmingham and Midland Eye Hospital, Birmingham, UK.

Naveed Shams

Chief Science Officer, Head, Global R&D, Santen Pharmaceutical Co. Ltd.

Kuldev Singh

Professor of Ophthalmology and Director of Glaucoma Service, Stanford University Medical Center, Stanford, USA.

Chelvin Sng

Consultant and Assistant Professor, National University Hospital, Singapore.

Jay Stark

Global Director – Surgical Glaucoma, Alcon Laboratories.

Carol Stiff

Senior Marketing Director, Santen Pharmaceutical Co. Ltd.

Satoshi Suzuki

Head of Corporate Development Division, Santen Pharmaceutical Co. Ltd.

> T

Donald Tan

Arthur Lim Professor, Singapore National Eye Centre, Duke-NUS Medical School.

Yougin Tian

Associate Director, Global Medical Affairs, Santen Pharmaceutical Co. Ltd.

· Adnan Tufail

Consultant Ophthalmologist Moorfields Eye Hospital, Professor, UCL Institute of Ophthalmology, London, UK.

> W

Hogan Wan

Vice President Healthcare Investment Banking, JP Morgan, Hong Kong, China.

Ningli Wang

Director and the Vice President of the Eye Center of Beijing Tongren Hospital, Beijing, China.

· Zheng Wang

Professor and director, Aier Eye Hospital Group, China.

Dietrich Wolf

CEO, EyeTechCare.

Ian Wong

Clinical Associate Professor of Ophthalmology Department of Ophthalmology. Li Ka Shing Faculty of Medicine, The University of Hong Kong, China.

· Tien Yin Wong

Medical Director, Singapore National Eye Centre.

· Tina Wong

Head and Senior Consultant of the Glaucoma Department at Singapore National Eye Centre.

• Prof Anthony Wu GBS JP (胡定旭教授),

Standing Committee Member, Chinese People's Political Consultative Conference National Committee.

> X

Fay Xing

Partner, Wuxi Healthcare Ventures, Shanghai, China.

> Z

Roland Zaha

WaveLight Global Head of Product Support / Manufacturing Science & Technology, Alcon Laboratories.

· Benny Chung Yin Zee

Professor and Assistant Dean, The Chinese University of Hong Kong, China.

· Xiulan Zhang

Professor and Deputy Director of Glaucoma Service, Zhongshan Ophthalmic Center.

Haogang Zhu

Professor, Department of Computer Science Beihang University, Founder of Uni-Ledger.





Ophthalmology Is Our Singular Focus

We Are Constantly Exploring New Possibilities in Eye Care

With a singular focus on eye care, all our efforts go into advancing the ocular health of patients. That's the Santen Way.

Discover more at www.santen.com